Skip to content
Screener

Halozyme Therapeutics HALO Q2 2025 earnings

Reported August 5, 2025 · After market close

Revenue$325.7MMiss by $5.1M
EPS$1.54Beat by $0.31
Revenue estimate$330.8M
EPS estimate$1.23

Next report

Nov 2, 2026 (in a month)
Revenue estimate$482.3M
EPS estimate$2.25

Financials

Q2 2025

Income statement

See full
Revenue$325.7M+40.8%
Gross profit$279.4M+45.7%
Operating income$202.4M+72.7%
Net income$165.2M+77.1%
EPS (diluted)$1.33+84.7%

Balance sheet

See full
Cash & equivalents$61.9M-67.1%
Total debt$1.5B+0.3%
Total equity$332.7M+15.0%
Total assets$2.1B+4.3%

Cash flow

See full
Operating cash flow$99.7M+78.7%
CapEx$1.6M-39.5%
Free cash flow$98.1M+84.4%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$6.64B-0.1%
Enterprise value$8.12B+1.6%
P/E11.9×-7.8×
P/S5.6×-2.0×

Profitability

See full
Gross margin84.2%+4.2pp
Operating margin57.9%+11.9pp
Net margin47.3%+8.7pp
FCF margin45.9%-0.9pp

Returns & leverage

See full
Return on equity179.1%+26.0pp
Debt / equity4.6×-0.7×
Current ratio8.4×+1.0×

Segments

By product

See full
Royalties$205.6M+64.6%
Proprietary product sales$46.5M+5.2%
Event-based development and regulatory milestones and other fees$24.5M-3.9%
Bulk rHuPH20 sales$23.3M-5.5%
Device partnered product sales$11.8M+16.6%

By geography

See full
All other foreign$8.3M+250%

FAQ

When did Halozyme Therapeutics report Q2 2025 earnings?
Halozyme Therapeutics (HALO) reported Q2 2025 earnings on August 5, 2025 after market close.
What were Halozyme Therapeutics's Q2 2025 revenue and EPS?
Halozyme Therapeutics reported revenue of $325.7M and eps of $1.54 for Q2 2025.
Did Halozyme Therapeutics beat estimates in Q2 2025?
Revenue missed the consensus estimate of $330.8M by $5.1M. EPS beat the consensus estimate of $1.23 by $0.31.
How did Halozyme Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 40.8% from $231.4M a year earlier and eps grew 69.2% from $0.91.
Where can I find Halozyme Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001159036-25-000033) and the 10-Q periodic report (0001159036-25-000034) directly on SEC EDGAR. The filing index links above go to sec.gov.